{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:59Z","timestamp":1793672999060,"version":"4.5.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uveitis is a common extra-articular manifestation of ankylosing spondylitis (AS), and a systematic analysis of the effects of biologics on new-onset and recurrent uveitis is clinically important.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a network meta-analysis (NMA) to assess the impact of anti-TNF-\u03b1 (adalimumab, etanercept, golimumab, and infliximab), IL-17 inhibitors (secukinumab, bimekizumab, and ixekizumab), and JAK inhibitors (tofacitinib and upadacitinib) on new-onset and recurrent uveitis. Phase II\/III double-blind randomized controlled trials and cohort studies were included. The relative risk (RR) was estimated, and drug efficacy was ranked based on the surface under the cumulative ranking curve (SUCRA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 17 articles with 18 studies and 11,529 AS patients were included. For new-onset uveitis, adalimumab reduced the risk significantly compared to etanercept and golimumab (RR: 0.30, 0.61), while etanercept increased the risk compared to golimumab and infliximab (RR: 2.03, 2.47). The SUCRA demonstrated that upadacitinib (84.0%) exhibited better efficacy, while ixekizumab (8.7%) was less effective than placebo (29.9%). For recurrent uveitis, adalimumab significantly reduced the risk compared to etanercept (RR: 0.70), while etanercept increased the risk compared to golimumab and infliximab (RR: 1.37, 1.70). Bimekizumab 160 mg and 320 mg were the most efficacious (SUCRA: 83.9%, 83.5%). A comprehensive analysis revealed that bimekizumab 320 mg and 160 mg were the most effective in reducing the incidence of uveitis. Ixekizumab and secukinumab were less effective than placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>JAK inhibitors were more effective for new-onset uveitis in AS patients. Inhibition of IL-17A (secukinumab and ixekizumab) alone might increase the risk of uveitis, while simultaneous inhibition of IL-17A and IL-17F (bimekizumab) significantly reduced the risk. Etanercept increased the risk of uveitis compared to other TNF-\u03b1 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1556313","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:10:44Z","timestamp":1750378244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Xu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiquan","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21619","article-title":"Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria","volume":"54","author":"Rudwaleit","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546429","article-title":"Divergent B-cell and cytotoxic TNK cell activation signatures in HLA-B27-associated ankylosing spondylitis and acute anterior uveitis","volume":"16","author":"Mahyari","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2170251","article-title":"Global research status regarding uveitis in the last decade","volume":"32","author":"Lu","year":"2024","journal-title":"Ocul Immunol Inflammation"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2262028","article-title":"Revealing academic evolution and frontier pattern in the field of uveitis using bibliometric analysis, natural language processing, and machine learning","volume":"32","author":"Lu","year":"2024","journal-title":"Ocul Immunol Inflammation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.811664","article-title":"Uveitis as a risk factor for developing acute myocardial infarction in ankylosing spondylitis: A national population-based longitudinal cohort study","volume":"12","author":"Lai","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.959848","article-title":"Uveitis increases the risk of stroke among patients with ankylosing spondylitis: A nationwide population-based longitudinal study","volume":"13","author":"Tsung","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12967-023-04228-x","article-title":"Comprehensive profiling of extracellular vesicles in uveitis and scleritis enables biomarker discovery and mechanism exploration","volume":"21","author":"Wu","year":"2023","journal-title":"J Transl Med"},{"key":"B11","article-title":"Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients","volume":"38","author":"Choi","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030631","article-title":"Risk of acute anterior uveitis in ankylosing spondylitis according to the type of tumor necrosis factor-alpha inhibitor and history of uveitis: A nationwide population-based study","volume":"11","author":"Ahn","year":"2022","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis","volume":"27","author":"van der Linden","year":"1984","journal-title":"A Proposal Modif New York Criteria Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","first-page":"107363","DOI":"10.1016\/j.phrs.2024.107363","article-title":"Homodimerization of CB(2) cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling","volume":"208","author":"Navarro","year":"2024","journal-title":"Pharmacol Res"},{"key":"B18","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells B.S.","year":"2021"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42440","article-title":"and inflammation in the eye","volume":"120","author":"Caspi","year":"2010","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.05.005","article-title":"New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases","volume":"41","author":"Wendling","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042366","article-title":"Pharmacogenomics of anti-TNF treatment response marks a new era of tailored rheumatoid arthritis therapy","volume":"23","author":"Wysocki","year":"2022","journal-title":"Int J Mol Sci 23"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway","volume":"121","author":"L\u00fcgering","year":"2001","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitiS (FOCUS) initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"J Ophthalmic Inflammation Infect"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.immuni.2020.06.022","article-title":"The cytokine IL-17A limits th17 pathogenicity via a negative feedback loop driven by autocrine induction of IL-24","volume":"53","author":"Chong","year":"2020","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113599","article-title":"Biotherapies in uveitis","volume":"9","author":"Leclercq","year":"2020","journal-title":"J Clin Med 9"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.02.001","article-title":"Janus kinase-1 and 3 in ankylosing spondylitis","volume":"118","author":"Liao","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.64.12.28","article-title":"Therapeutic effects of upadacitinib on experimental autoimmune uveitis: insights from single-cell analysis","volume":"64","author":"Huang","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.v74.12","article-title":"Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase IIb randomized controlled trial and its open-label extension study","volume":"74","author":"Baraliakos","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.2019.71.issue-4","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study","volume":"45","author":"Deodhar","year":"2018","journal-title":"J Rheumatol"},{"key":"B50","article-title":"Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis","volume":"28","author":"Mart\u00edn-Mola","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ajo.2016.07.016","article-title":"Anti-TNF\u03b1 Treatment for HLA-B27-positive ankylosing spondylitis-related uveitis","volume":"170","author":"Kim","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030912","article-title":"Comparison of incidence or recurrence of anterior uveitis in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors","volume":"13","author":"Kwon","year":"2024","journal-title":"J Clin Med 13"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1556313\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:10:46Z","timestamp":1750378246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1556313\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2025.1556313"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1556313","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1556313"}}